Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Marketing Surveillance to evaluate the safety of 9-Valent Human Papillomavirus Vaccine through the Vaccine Adverse Event Reporting System (VAERS)

Trial Profile

Post-Marketing Surveillance to evaluate the safety of 9-Valent Human Papillomavirus Vaccine through the Vaccine Adverse Event Reporting System (VAERS)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Human papillomavirus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Nov 2019 Results assessing Safety of the 9-Valent Human Papillomavirus Vaccine published in the Pediatrics
    • 19 Nov 2018 New trial record
    • 07 Oct 2018 Results presented at the IDWeek 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top